RKVTF (Rakovina Therapeutics) Other Current Liabilities: $0.00 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

RKVTF Rakovina Therapeutics Inc RKVTF
27 GF Score
Price $0.07
! 1 Warning Sign
View Full Analysis

What is Rakovina Therapeutics Other Current Liabilities?

Rakovina Therapeutics RKVTF 27 Other Current Liabilities is $0.00 Mil as of Mar. 2026. GuruFocus rates RKVTF with a GF Score™ of 27/100. The stock has 1 warning sign investors should review.

Rakovina Therapeutics's other current liabilities for the quarter that ended in Mar. 2026 was $0.00 Mil.

Rakovina Therapeutics Other Current Liabilities Related Terms

Rakovina Therapeutics Other Current Liabilities Historical Data

* Premium members only.

The historical data trend for Rakovina Therapeutics's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Rakovina Therapeutics Other Current Liabilities Chart

Rakovina Therapeutics Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Liabilities
0.00 0.00 0.00 0.00 0.00

Rakovina Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
RKVTF
27GF Score
Rakovina Therapeutics Inc RKVTF
Other Current Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Rakovina Therapeutics Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.

What does a Other Current Liabilities of $0.00 Mil mean?
Rakovina Therapeutics (RKVTF) has a Other Current Liabilities of $0.00 Mil as of Mar. 2026. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Rakovina Therapeutics.
Is Rakovina Therapeutics' Other Current Liabilities too high?
Rakovina Therapeutics' current Other Current Liabilities is $0.00 Mil. Overall, Rakovina Therapeutics has a GF Score™ of 27/100, reflecting its overall financial health beyond just this single metric.
How does Rakovina Therapeutics' Other Current Liabilities compare to VRTX and REGN?
Rakovina Therapeutics' Other Current Liabilities of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Liabilities for a Biotechnology company?
A good Other Current Liabilities depends on the Biotechnology industry context. However, Other Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Liabilities mean?
A high Other Current Liabilities can signal that a stock is expensive relative to its fundamentals. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Rakovina Therapeutics. Rakovina Therapeutics's current Other Current Liabilities is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rakovina Therapeutics stock overvalued right now?
Rakovina Therapeutics (RKVTF) has a current Other Current Liabilities of $0.00 Mil. The current Other Current Liabilities is $0.00 Mil. Rakovina Therapeutics' overall GF Score™ is 27/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Liabilities calculated?
Other Current Liabilities is calculated from a company's financial statements. For Rakovina Therapeutics (RKVTF), the current Other Current Liabilities is $0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Rakovina Therapeutics Business Description

Other Exchanges 7JO0:GermanyRKV:Canada
Address 999 West Broadway, Suite 720, Vancouver, BC, CAN, V5Z 1K5
Rakovina Therapeutics Inc is a biopharmaceutical research company focused on the development of cancer treatments. Its work is based on technologies for targeting the DNA-damage response powered by Artificial Intelligence (AI) using proprietary, generative AI platforms. By using AI, it can review and optimize drug candidates at a greater pace. The company has established a pipeline of distinctive DNA-damage response inhibitors to advance one or more drug candidates into human clinical trials in collaboration with pharmaceutical partners. Its drug development pipeline consists of candidates like kt-5000AI, kt-2000AI, and kt-3283, targeting solid tumours and PARP-resistant adult and childhood cancers.
27GF Score

Get the complete analysis for RKVTF

Other Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.07
Price